Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Shionogi reports ras transformation inhibitor

Aug. 23, 1996

Farnesyl transferase inhibitors from Pierre Fabre

Aug. 23, 1996

Study indicates ISIS-3521/CGP-64128A inhibits tumor growth

Aug. 23, 1996

IDEC-Y2B8/IDEC-C2B8 combination undergoes phase I/II

Aug. 23, 1996

Fareston launched in the U.K.

Aug. 23, 1996

Phase I pharmacokinetic study of asulacrine initiated

Aug. 23, 1996

Japanese investigators describe antileukemia activity of drupangtonine

Aug. 23, 1996

Taiho discloses antitumor nucleoside drugs

Aug. 23, 1996

Somatix in-licenses Salk gene transfer technology

Aug. 16, 1996

StressGen licenses cancer gene therapy technology from MRC

Aug. 16, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...